The introduction of blood biomarkers for Alzheimer’s disease is revolutionizing the biological diagnosis of this disease, enabling faster diagnosis i1
Numerous scientific studies have identified preventable potential risk factors for the development of dementia. Fourteen of these factors and their i1
HUB Alzheimer Barcelona is a pioneering collaborative initiative rooted in a commitment to transform the future of research and provide support for p1
Researchers at the Clínic-IDIBAPS led a study published in the Alzheimer’s & Dementia journal on the relationship between the integrity of the locus1
The centre becomes the first in Spain to use blood biomarker p-tau217, which offers a more accurate and less invasive diagnosis and marks a paradigm1
With the expansion of the Day Hospital for Neurodegenerative Diseases at the Clínic Barcelona Hospital, it will be possible to receive over 15,000 vi1
Frontotemporal dementia (FTD) and Alzheimer's disease are two different forms of dementia, which can often be confused due to sharing some of the sym1
Biological sex, that is, being born male or female, can influence different aspects of early-onset Alzheimer's disease (symptoms seen before the age1
Gene therapy applied to the treatment of neurodegenerative diseases is a promising field of study, and consists of modifying a patient's genes to slo1
A study by the hospital Clínic Barcelona-IDIBAPS, published in the journal Neurology, confirms the usefulness of a blood-based biomarker to diagnose1
